Community Practice Connections™: Leveraging Tumor and Immune Biology in Endometrial Cancer: A New Era of Rational Treatment Design

Release Date: May 27, 2021
Expiration Date: May 27, 2022

Activity Overview

In patients with uterine corpus cancers, the American Cancer Society projects a total of 66,570 new diagnoses and 12,940 deaths in 2021. Advances in an understanding of the pathobiology associated with endometrial cancer has provided new targets, which have led to the development of novel agents and combinations involving immunotherapy, tyrosine kinase inhibitors, and agents for specific genomic alterations.

This Community Practice Connections^™ program provides an in-depth review of some of the key highlights from The Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer, held in March 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with endometrial cancer, placing recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and would help to reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai, Inc. and Merck & Co., Inc.
 

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Detail key aspects of tumor biology in endometrial cancer that guide prognosis and treatment decision-making
• Apply emerging clinical data to challenging treatment scenarios across lines of care in endometrial cancer
• Evaluate clinical trial data regarding emerging treatment strategies and combination therapies in endometrial cancer
• Outline strategies to monitor for, manage, and mitigate adverse events associated with current treatments in endometrial cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Ursula A. Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Consultant: Merck, NextCure, Novartis; Other: Honorarium for speaking engagements from Merck.

Amanda Nickles Fader, MD
Associate Professor, Gynecology and Obstetrics
Vice Chair, Gynecologic Surgical Operations
Director, Center for Rare Gynecologic Cancers
Johns Hopkins Medicine
Baltimore, MD

Disclosures: Consultant: Merck, Eisai.

Mansoor Raza Mirza, MD
Chief Oncologist, Rigshospitalet, Copenhagen University Hospital
Medical Director, Nordic Society of Gynecological Oncology – Clinical Trial Unit
Founding Executive Member, European Network of Gynaecological Oncological Trials Group
Board of Directors, Gynaecologic Cancer Inter Group
Faculty, European Society of Medical Oncology
Founding Executive Member, European Society of Gynecological Oncology
Copenhagen, Denmark

Disclosures: Grant Research: Apexigen, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Pfizer, Tesaro-GlaxoSmithKline, Ultimovacs; Consultant: AstraZeneca, Biocad, Clovis Oncology, Geneos Therapeutics, Genmab, GlaxoSmithKline, Karyopharm Therapeutics, Merck, Mersana, MSD, Oncology Venture, Pfizer, Roche, Seattle Genetics, Sera Prognostics, SOTIO, Takeda, Tesaro, Zai Lab; Shareholder: Karyopharm Therapeutics, Sera Prognostics.

Brian M. Slomovitz, MD, MS
Professor of Obstetrics and Gynecology, Florida International University
Gynecologic Oncology, Broward Health
Fort Lauderdale, FL

Disclosures: Consultant: AbbVie, AstraZeneca, Clovis Oncology, GlaxoSmithKline, Genentech, Myriad, GOG Foundation.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.